The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

Shares of GSK PLC GSK rose 1.02% to £14.30 Wednesday, on what proved to be an all-around positive trading session for the ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...